MabVax Therapeutics, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "MabVax Therapeutics, Inc. - Product Pipeline Review - 2014" provides data on the MabVax Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, MabVax Therapeutics, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from MabVax Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- MabVax Therapeutics, Inc. - Brief MabVax Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MabVax Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MabVax Therapeutics, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MabVax Therapeutics, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MabVax Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MabVax Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MabVax Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MabVax Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MabVax Therapeutics, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
MabVax Therapeutics, Inc. Snapshot 5
MabVax Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
MabVax Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
MabVax Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
MabVax Therapeutics, Inc. - Pipeline Products Glance 11
MabVax Therapeutics, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
MabVax Therapeutics, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
MabVax Therapeutics, Inc. - Drug Profiles 14
NSC-748933 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Sarcoma Vaccine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Neuroblastoma Vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Melanoma Vaccine 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Cell Lung Cancer Vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Vaccine for Breast Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
1-B7 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
5-B1 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MabVax Therapeutics, Inc. - Pipeline Analysis 24
MabVax Therapeutics, Inc. - Pipeline Products by Therapeutic Class 24
MabVax Therapeutics, Inc. - Pipeline Products by Target 25
MabVax Therapeutics, Inc. - Pipeline Products by Route of Administration 26
MabVax Therapeutics, Inc. - Pipeline Products by Molecule Type 27
MabVax Therapeutics, Inc. - Pipeline Products by Mechanism of Action 28
MabVax Therapeutics, Inc. - Recent Pipeline Updates 29
MabVax Therapeutics, Inc. - Locations And Subsidiaries 30
Head Office 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
MabVax Therapeutics, Inc., Key Information 5
MabVax Therapeutics, Inc., Key Facts 5
MabVax Therapeutics, Inc. - Pipeline by Indication, 2014 8
MabVax Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
MabVax Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
MabVax Therapeutics, Inc. - Phase II, 2014 11
MabVax Therapeutics, Inc. - Phase I, 2014 12
MabVax Therapeutics, Inc. - Preclinical, 2014 13
MabVax Therapeutics, Inc. - Pipeline by Therapeutic Class, 2014 24
MabVax Therapeutics, Inc. - Pipeline by Target, 2014 25
MabVax Therapeutics, Inc. - Pipeline by Route of Administration, 2014 26
MabVax Therapeutics, Inc. - Pipeline by Molecule Type, 2014 27
MabVax Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 28
MabVax Therapeutics, Inc. - Recent Pipeline Updates, 2014 29